|
Cardiology
Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension
Jinwoo Lee, Seong Jin Jo, Youngjin Cho, Ji Hyun Lee, Il-Young Oh, Jin Joo Park, Young-Seok Cho, Dong-Ju Choi
Korean J Intern Med. 2021;36(Suppl 1):S123-S131. Published online February 10, 2021
Background/Aims: There are concerns that the use of renin-angiotensin system (RAS) blockers may increase the risk of being infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or progressing to a severe clinical course after infection. This this study aimed to investigate the i..
|
|
|
Different therapeutic associations of renin-angiotensin system inhibitors with coronavirus disease 2019 compared with usual pneumonia
Hae-Young Lee, Juhee Ahn, Juhong Park, Chang Kyung Kang, Sung-Ho Won, Dong Wook Kim, Jong-Heon Park, Ki-Hyun Chung, Joon-Sung Joh, JI Hwan Bang, Cheong Hee Kang, Myoung-don Oh, Wook Bum Pyun; The Korean Society of Hypertension; The National Committee for Clinical Management of Emerging Infectious Diseases
Korean J Intern Med. 2021;36(3):617-628. Published online April 16, 2021
Background/Aims: Although it is near concluded that renin-angiotensin system inhibitors do not have a harmful effect on coronavirus disease 2019 (COVID-19), there is no report about whether angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) offer any protective..
|
|
|
Pulmonology
Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis
Hyun Woo Lee, Jae Kyung Suh, Eunjin Jang, Sang-Min Lee
Korean J Intern Med. 2021;36(2):371-381. Published online April 9, 2020
Background/Aims: Inhibitors of the renin-angiotensin system, angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), reportedly have anti-inflammatory effects. This study assessed the association of prior use of ACE inhibitors and ARBs with sepsis-related clinical..
|
|
|
Cardiology
Olmesartan is not associated with the risk of enteropathy: a Korean nationwide observational
cohort study
Seng Chan You, Hojun Park, Dukyong Yoon, Sooyoung Park, Boyoung Joung, Rae Woong Park
Korean J Intern Med. 2019;34(1):90-98. Published online November 27, 2017
Background/Aims: Olmesartan, a widely used angiotensin II receptor blocker (ARB), has been linked to sprue-like enteropathy. No cases of olmesartan-associated enteropathy have been reported in Northeast Asia. We investigated the associations between olmesartan and other ARBs and the incidence of ent..
|
|
|
Nephrology
Effect of low-dose valsartan on proteinuria in normotensive immunoglobulin A nephropathy with minimal proteinuria: a randomized trial
Young-Il Jo, Ha-Young Na, Ju-Young Moon, Sang-Woong Han, Dong-Ho Yang, Sang-Ho Lee, Hyeong-Cheon Park, Hoon-Young Choi, So-Dug Lim, Jeong-Hae Kie, Yong-Kyu Lee, Sug-Kyun Shin
Korean J Intern Med. 2016;31(2):335-343. Published online February 15, 2016
Background/Aims: Immunoglobulin A nephropathy (IgAN) is a generally progressive disease, even in patients with favorable prognostic features. In this study, we aimed to investigate the antiproteinuric effect and tolerability of low-dose valsartan (an angiotensin II receptor blocker) therapy in normo..
|
|
|
Additional antihypertensive effect of magnesium supplementation with an angiotensin II receptor blocker in hypomagnesemic rats
Kyubok Jin, Tae Hee Kim, Yeong Hoon Kim, Yang Wook Kim
Korean J Intern Med. 2013;28(2):197-205. Published online February 27, 2013
Background/AimsMagnesium (Mg) is an essential element for vascular function and blood pressure regulation. Several studies have demonstrated that Mg concentration is inversely associated with blood pressure, and that Mg supplementation attenuates hypertension. The purpose of t..
|
|
|
